Lymphopenia (also known as lymphocytopenia) is a blood disorder that involves a reduced level of lymphocytes, which are white blood cells that help protect you from infection. Lymphocytes are an ...

The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and ...

Medically reviewed by Geetika Gupta, MD Having a low white blood cell (WBC) count, also known as leukopenia, means that your ...

FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare ...

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows ...

HIV viraemia with CD4 + T-cell lymphopenia is associated with an increased frequency of immature transitional B cells. This increase is also associated with increased serum levels of interleukin-7.

Other adverse events were low-grade, manageable, or mechanistically based (e.g. transient lymphopenia after the first dose only) . Of the two patients with detectable B cells at baseline, both ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful ...

XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric ...